Margaret Juliana Mcelrath - Vaccines

Author Information

Margaret Juliana McElrath is a prominent researcher affiliated with the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center in Seattle, WA. Her work primarily focuses on vaccine development and infectious diseases, contributing significant insights into immune responses and vaccine efficacy.

Research Contributions

Margaret Juliana McElrath has made substantial contributions to the field of vaccinology and infectious diseases. Her research covers a wide range of topics including immune protection against SARS-CoV-2 variants, the immune response to malaria and Ebola vaccinations, and the effects of booster vaccinations for COVID-19. Her work is pivotal in understanding the immune mechanisms underlying vaccine responses and informing public health strategies for vaccination programs.

Aliases

Margaret Juliana McElrath is known in the academic community by several aliases including M. Juliana McElrath, Margaret J. McElrath, Maggie McElrath, and M. J. McElrath, among others. These variations are often used in scientific publications and collaborations.

Publication and Citation Metrics

Metric	Value
Total Papers	477
Citation Count	25,086
H-index	73

Publications:

Defining the risk of SARS-CoV-2 variants on immune protection.

DOI: 10.1038/s41586-022-04690-5

Year: 2022

Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity

DOI: 10.1371/journal.ppat.1010282

Year: 2022

BCG revaccination qualitatively and quantitatively enhances SARS-CoV-2 spike-specific neutralizing antibody and T cell responses induced by the COVISHIELD™ vaccine in SARS-CoV-2 seronegative young Indian adults

DOI: 10.21203/rs.3.rs-1395683/v1

Year: 2022

Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study

DOI: 10.7554/eLife.70393

Year: 2022

Homologous and Heterologous Covid-19 Booster Vaccinations

DOI: 10.1056/NEJMoa2116414

Year: 2022

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

DOI: 10.1371/journal.pmed.1003865

Year: 2022

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply

DOI: 10.1016/S0140-6736(22)00329-4

Year: 2022

Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

DOI: 10.1002/cti2.1360

Year: 2022

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

DOI: 10.1371/journal.pmed.1003813

Year: 2021

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

DOI: 10.1101/2021.04.19.21255739

Year: 2021

Which Vaccines Have Shown to Lower Hospitalization Rates?

Who Should Get the MMR Vaccine?

Who Should Be Involved in Community Engagement?

What is Herd Immunity?

What is Vaccine Access?

What is a Pathogen?

What is Vaccine Soreness?

Can Soreness Be Prevented?

How is Vaccine Training Delivered?

Why is Informed Consent Important for Vaccines?

Partnered Content Networks

Relevant Topics